Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Journal of Research in Pharmacy
2023 , Vol 27 , Issue 2
pH-dependent pulsatile delivery of Ambrisentan for the treatment of hypertension
1Department of Pharmaceutics, SVKM NMIMS School of Pharmacy and Technology Management, Shirpur, Dhule, India-42540
DOI :
10.29228/jrp.365
The greatest number of mortality in the world occurred due to hypertension. Several bodily
functions are based on circadian rhythm including hypertension. The stimulation of the sympathetic
nervous system in the early morning hours resulted in accelerating blood pressure which is a highly
dangerous condition. This lead to cardiac failure and damage to the vital organs of the body. The current
research focuses on pulsatile delivery of Ambrisentan for the treatment of high blood pressure which
released the medicament at the right time and the right place. Primarily, core tablets were prepared with
Ambrisentan. The compatibility of Ambrisentan with excipients was confirmed by FTIR analysis. The core
tablets were evaluated for flowing characteristics which showed better flowing behavior and optimized
core batch CT6 showed consolidation index 16.07±0.11 and angle of repose 27.02±0.14. Moreover, due to the
least disintegration time (2.23±0.10) and greater dissolution release of 99.70 % ±0.49, CT6 was selected as an
optimized core tablet for pulsatile delivery. Further, the combination of Eudragit L100 and ethyl cellulose
were utilized for coating purposes in different proportion were utilized for achieving the desired lag time
of 6 hrs. The optimized batch PC6 (Eudragit L100: EC 10) which comprised of 25:75 proportion showed a
lag time of 6 hours, cumulative release of 99.25 % and content uniformity of 99.29±0.82. The dissolution
release profile predicted zero-order release for Ambrisentan pulsatile tablets. The accelerated stability
testing showed minimal loss of drug content when exposed at 40 0C and 75 % relative humidity without
altering lag time.
Keywords :
Ambrisentan; Pulmonary hypertension; Pulsatile delivery; Eudragit L100; Ethylcellulose